NXGL· Health Care› Medical Instruments & Supplies

NexGel, Inc

Stage 4 · Declining · week 47

As of Oct 22, 2026, NexGel is in Stage 4, the downtrend phase, now in week 47 (since Nov 18, 2025). It closed at $4.76, 90.9% below its 52-week high and below its 200-day average, which is falling.

$4.76

-7.93% today

$2.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NXGL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S2 31w

S4 18w

S4 48w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 12w → S4 5w → S1 3w → S2 15w → S3 12w → S4 1w → S3 1w → S2 31w → S3 6w → S4 18w → S1 4w → S4 5w → S1 5w → S4 48w current

Total tracked: 166 weeks across 15 stage runs.

NXGL among Medical Instruments & Supplies47th of 51 by relative strength

All 51 →

Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	PLSEPulse Biosciences, Inc	Stage 2 · wk 34	98	+1.3%
2	PDEXPro-Dex, Inc.	Stage 2 · wk 36	97	−13.3%
3	HBIOHarvard Bioscience, Inc.	Stage 2 · wk 11	95	+3.6%
4	ATRCAtriCure, Inc.	Stage 2 · wk 10	89	−1.1%
5	WSTWest Pharmaceutical Services, Inc.	Stage 2 · wk 24	82	+4.8%
6	BDXBecton, Dickinson and Company	Stage 2 · wk 11	81	+9.8%
7	ICUIICU Medical, Inc.	Stage 3 · wk 1	81	+3.1%
8	OSUROraSure Technologies, Inc.	Stage 3 · wk 8	75	−4.8%
…47	NXGLNexGel, Inc	Stage 4 · wk 47	6	−11.2%

vs 52W High

-90.9%

$3.00 lo$52.20 hi

90.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 47

1w13w26w

Week 47, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-64.5%

200 DMA: $13.42 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.24x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-11.2%

-45.8%

-61.0%

YTD

-86.9%

-91.4%

Scan Membership

Breakout Watch

Latest: 2024-07-25

3 appearances in last 60 days. First seen: 2023-05-10.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 47 · Vol 0.24x

2026-10-21S4

Wk 47 · Vol 0.39x

2026-10-20S4

Wk 47 · Vol 0.21x

2026-10-19S4

Wk 46 · Vol 0.37x

2026-10-16S4

Wk 46 · Vol 0.41x

2026-10-15S4

Wk 46 · Vol 1.27x

2026-10-14S4

Wk 46 · Vol 52.81x

2026-10-13S4

Wk 46 · Vol 1.20x

2026-10-12S4

Wk 45 · Vol 3.38x

2026-10-09S4

Wk 45 · Vol 11.05x

2026-10-08S4

Wk 45 · Vol 1.46x

2026-10-07S4

Wk 45 · Vol 0.70x

Moving averages & range

50 DMA

$5.69

200 DMA

$13.42

52W High

$52.20

52W Low

$3.00

5D Low

$4.76

Resistance levels (recent highs)

20d High

$5.80

60d High

$11.30

120d High

$12.30

250d High

$51.80

Next resistance

+21.8%

to 20d High

ROE

-115.1%

Profit margin -51.3%

Dividend Yield

0.00%

P/B 0.5

NexGel: quick answers

What stage is NexGel in?

As of Oct 22, 2026, NexGel (NXGL) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 18, 2025 and is in week 47. What the four stages mean

Is NexGel in an uptrend?

No. NexGel is in a Stage 4 downtrend. It trades 64.5% below its 200-day average, which is falling.

How far is NexGel from its 52-week high?

NexGel closed at $4.76 on Oct 22, 2026, 90.9% below its 52-week high of $52.20. Its 52-week low is $3.00.

How has NexGel performed over the past year?

As of Oct 22, 2026, NexGel is down 91.4% over the past year and down 86.9% so far in 2026.

Which sector and industry is NexGel in?

NexGel is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.